8-K: NeOnc NEO100 Shows Strong Brain Cancer Response, Survival

NeOnc Technologies announced updated Phase 1/2a clinical results for intranasal NEO100, showing significant radiographic response and long-term survival in recurrent IDH1-mutant astrocytoma patients.

Summary

• Updated clinical results from Phase 1/2a and compassionate care studies for intranasal NEO100 involved a cohort of 24 patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma.
• 21% (5 of 24 patients) achieved a significant radiographic response, confirmed by contrast-enhanced and perfusion MRI, a rate that markedly exceeds the <8% response typically observed with salvage therapies for recurrent gliomas.
• 44% of patients in the Phase 2a study achieved six-month progression-free survival (PFS-6), surpassing the 21-31% benchmark reported in historical datasets for IDH1-mutant recurrent high-grade gliomas.
• 33% (8 of 24 patients) remained alive 18 months after initiation of NEO100, demonstrating long-term survival with a median overall survival of 88 months.
• No significant toxicity was reported with intranasal administration of NEO100, even with prolonged, chronic use.
• The NEO100-01 Phase 2a clinical study has achieved full enrollment of 25 patients.
• The full FDA six-month readout for the NEO100 trial is expected by May 12, 2026.

Sentiment

Score: 9

Explanation: The clinical trial results for NEO100 show significantly improved radiographic response, progression-free survival, and long-term survival rates compared to historical benchmarks for a highly aggressive and difficult-to-treat brain cancer. The lack of significant toxicity further enhances the positive outlook, suggesting a potential paradigm shift in treatment. Management and scientific advisors express strong optimism.

Positives

• Significant radiographic response rate of 21% (5 of 24 patients) for NEO100, which is substantially higher than the <8% typically seen with salvage therapies for recurrent gliomas.
• High 6-month progression-free survival (PFS-6) rate of 44% in the Phase 2a study, exceeding historical benchmarks of 21-31% for IDH1-mutant recurrent high-grade gliomas.
• Durable long-term survival demonstrated by 33% (8 of 24 patients) remaining alive 18 months post-initiation of NEO100, with a median overall survival of 88 months.
• Excellent tolerability with no significant toxicity reported, even with prolonged, chronic intranasal administration.
• NEO100 is a CNS-penetrant metabolic therapy, offering a potential paradigm shift from palliative care to measurable, durable disease control.
• The NEO100-01 Phase 2a clinical study has achieved full enrollment.
• The drug has FDA Fast-Track and Investigational New Drug (IND) status.

Risks

• Forward-looking statements are subject to risks and uncertainties, and future events may differ materially from those anticipated.
• Risks and uncertainties are outlined in the company's most recent Annual Report on Form 10-K and subsequent filings.
• Specific risks mentioned include the failure to finalize an agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
• The FDA's perception of data and regulatory pathways (e.g., breakthrough therapy, fast track, orphan drug designation) can change.
• The full mechanisms of NEO100 are not yet fully understood, including resistance mechanisms and optimal combination therapies.

Future Outlook

The company believes the current data represents a potential paradigm shift in the treatment of brain cancer, moving beyond palliation toward measurable, durable disease control and a possible new standard of care in malignant gliomas. The data provides translational momentum to support future Phase 2b/3 and global trials. The company is exploring combination therapies with standard of care treatments like temozolomide, CCNU/Lomustine, or other inhibitors, including immunotherapy. The company will pursue breakthrough therapy, fast track, or orphan drug designation expansion for NEO100. Full FDA six-month readout for the NEO100 trial is expected by May 12, 2026. The clinical pipeline continues to expand to include other applications of NEO100 and NEO212, including NEO100-02 for meningiomas (7/30 enrolled), NEO212 (oral) for all brain tumors (13/15 enrolled in last cohort, MTD not reached), and NEO100-03 for pediatric brain tumors (starting enrollment).

Management Comments

• Amir F. Heshmatpour, Executive Chairman, President & CEO: "With these data, we believe NeOnc stands at the threshold of a true game-changer for one of medicines greatest unmet needs—recurrent IDH1-mutant hi grade gliomas. For the first time, we’re witnessing evidence of meaningful radiographic responses and support for durable survival in patients who previously had few, if any, options."
• Amir F. Heshmatpour: "As we approach full enrollment of the NEO100 trial—and our full data readout six months post-enrollment—we believe this may represent a potential paradigm shift in the treatment of brain cancer. The data will speak for itself—and for the patients whose lives we are determined to transform."
• Dr. Thomas Chen, Founder, Vice-Chairman and Chief Medical Officer: "The data suggest that intranasal NEO100 may be the first central nervous system (CNS)-penetrant metabolic therapy capable of inducing durable response and multi-year survival in recurrent IDH1 mutant gliomas."
• Dr. Henry Friedman of Duke University: "The results from NEO100 signify a potential paradigm shift in the treatment of recurrent IDH1-mutant gliomas."
• Dr. Henry Friedman: "The thing that’s most striking to me, frankly, is less the responses than the duration of time that patients who were progressing go on the drug and stay on the drug. That is the single most important thing as far as I’m concerned."
• Dr. Alexandra M. Miller, Chief of Neuro-Oncology at NYU Langone: "NeOnc really represents a unique approach to the treatment of gliomas. And as I mentioned, I think particularly appealing is the ease of administration, the lack of significant side effects associated with the drug. And the fact that because there are so few side effects, it really has the potential to enable it to be layered on top of many of our other treatment strategies as well."
• Amir F. Heshmatpour: "As of today, NEO100 is fully enrolled, a pivotal achievement that positions us to deliver the full FDA six-month readout by May 12 of 2026. We are deeply encouraged by the safety, durability and clinically meaningful benefits we’ve seen to date, and even more inspired by what lies ahead."

Industry Context

Existing treatments for gliomas are largely inadequate, leaving patients with few options, most of which are palliative. There is an urgent unmet need for innovative new strategies, especially those with minimal side effects and easy administration, which NEO100 aims to address. The results suggest a potential move beyond palliation toward measurable, durable disease control, signaling a possible new standard of care in malignant gliomas. The field of neuro-oncology rarely sees agents that offer such meaningful hope, with comparisons made to the impact of temozolomide and Avastin in their early stages. The FDA's regulatory environment is noted as dynamic, with recent leadership changes (Rick Pazdur to Head of CDER) potentially impacting future review processes for breakthrough therapies.

Comparison to Industry Standards

• NEO100's radiographic response rate of 21% (5 of 24 patients) markedly exceeds the <8% response typically observed with salvage therapies for recurrent gliomas.
• NEO100's 6-month progression-free survival (PFS-6) rate of 44% surpasses the 21-31% benchmark reported in historical datasets for IDH1-mutant recurrent high-grade gliomas.
• The minimal toxicity of NEO100 differentiates it from standard salvage therapies, which often have significant side effects.
• The durable survival and long-term patient retention on the drug are highlighted as particularly significant compared to typical progression in this patient population.
• Dr. Henry Friedman, a distinguished neuro-oncology professor, compared the potential impact of NEO100 to that of Avastin, which quickly led to approval for recurrent disease and use in newly diagnosed disease with bulk disease present.

Stakeholder Impact

• Shareholders/Investors: Highly positive clinical results could significantly increase company valuation and investor confidence, especially given the unmet medical need.
• Patients with IDH1-mutant Astrocytoma: Potential for a "game-changer" therapy offering meaningful radiographic responses, durable survival, and improved quality of life with minimal toxicity, where few effective options previously existed.
• Medical Community/Neuro-oncologists: NEO100 could represent a new standard of care, shifting treatment paradigms from palliation to disease control.
• Employees: Positive clinical progress could boost morale and attract talent.
• Regulatory Authorities (FDA): The strong signal and favorable safety profile may warrant expedited review pathways like breakthrough therapy or fast track designation.

Next Steps

• Full FDA six-month readout for the NEO100 trial by May 12, 2026.
• Continued enrollment in NEO100-02 for meningiomas.
• Completion of enrollment in the last cohort for NEO212 (oral) for all brain tumors.
• Starting enrollment for NEO100-03, a pediatric application for brain cancer.
• Pursuit of breakthrough therapy, fast track, or orphan drug designation expansion for NEO100.
• Exploration of NEO100 in combination with standard of care therapies (temozolomide, CCNU/Lomustine, immunotherapy).
• Planning for future Phase 2b/3 and global trials (e.g., Cleveland Clinic, UAE, M42/IROS).

Key Dates

Recommendation

The clinical data presented for NEO100 in recurrent IDH1-mutant astrocytoma is exceptionally strong, demonstrating significantly superior radiographic response and progression-free survival rates compared to current salvage therapies, coupled with durable long-term survival and an excellent safety profile. This addresses a critical unmet medical need in a devastating disease. The potential for a "paradigm shift" and a "new standard of care" is high, as echoed by leading neuro-oncology experts. The drug's FDA Fast-Track and IND status, combined with plans for further trials and expedited regulatory pathways, suggest a clear path to market. This represents a pivotal value inflection point for the company, indicating substantial future growth potential and a compelling investment opportunity.

Keywords

NEO100, Astrocytoma, IDH1-mutant, Glioma, Brain Cancer, Clinical Trial, Phase 2a, Oncology, Biopharmaceutical, CNS Therapeutics, Intranasal Delivery, Progression-Free Survival, Radiographic Response, Long-Term Survival, Neuro-oncology